Intrinsiqq
Valion Bio, Inc. logo

Valion Bio, Inc. Financials

TIVC

Compare

All currency values in $ millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
~8.8:1 split
DEC 2024
~6.2:1 split
DEC 2023
~8.2:1 split
DEC 2022
~2.8:1 split
DEC 2021
Revenues
Revenue$0–$1$1$2$1
Cost of Revenue$1–$1$1$2$1
Gross Profit-$0–$0$0$0-$0
Operating Expenses
Selling & Marketing$1–$1$2$3$2
General & Administrative$4$5$3$5$6$3
Research & Development$2$3$1$2$2$1
Provision for Doubtful Accounts–$0$0$0–$0
Total Operating Expenses$5$8$4$9$10$6
Operating Income-$6-$8-$4-$8-$10-$6
Non-Operating
Net Interest Expense–-$0$0–––
Other Non-Operating Income (Expense)–-$0$0$0$0-$3
EBT (Earnings Before Tax)–––-$8-$10–
Income Tax Expense–$0$0–––
Earnings from Continuing Ops–-$8-$4–––
Net Income
Net Income-$8-$9-$6-$8-$10-$8
Per Share Data
Revenue Per Share$0.29–$2.71$25.21$323.38$611.72
EPS (Basic)$0.09-$7.84-$19.68-$176.80-$1,773.44-$4,131.00
EPS (Diluted)$0.48-$3.51-$19.68-$176.80-$1,773.44-$4,131.00
Weighted Avg Shares (Basic)1.3M1.2M287,370793,0439.7M3.5M
Weighted Avg Shares (Diluted)––287,370793,0439.7M3.5M
Shares Outstanding1.7M2.5M287,37046,649.5885,689.9752,054.863

Valion Bio (TIVC) financials: revenue, profit and margins

Valion Bio (TIVC) generated about n/a in revenue and -$19 million in net income over the trailing twelve months, growing at roughly -14.7% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Valion Bio profitable?+

Valion Bio reported about -$19 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Valion Bio growing?+

Valion Bio's revenue has compounded at roughly -14.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside TIVC's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with TIVC

CompareIntrinsic value
CUECue Biopharma, Inc.
$4.15-7.78%40
BYSIBeyondSpring Inc.
$0.33-24.49%20
CAPRCapricor Therapeutics Inc.
$7.59+0.80%10
MGNXMacrogenics Inc.
$1.96-1.01%28
VREOFVireo Growth Inc.
$5.23-2.24%30
NKTRNektar Therapeutics Inc.
$30.20-7.19%25
PTIXProtagenic Therapeutics, Inc.
$0.42-0.71%20
ABBVAbbVie Inc.
$286.20+0.94%49

Spot a number that looks wrong? Check it in TIVC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing TIVC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.